ElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For Migraine

Trending Investment Opportunities

Health Canada has approved ElectroCore Inc's ECOR gammaCore Sapphire family of products to prevent and treat migraine and cluster headache.
GammaCore Sapphire will be distributed in Canada by RSK Medical Inc, under an exclusive distribution agreement announced in January this year. The initial term of the agreement is three years.
In February this year, the FDA approved an expanded label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17.
Earlier in March, Australia's regulatory authority approved the device for primary headache disorders.
GammaCore non-invasive vagus nerve stimulator is a non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache.
It utilizes mild electrical stimulation to the vagus nerve that passes through the skin.
Price Action: ECOR shares are up 7.9% at $2.19 on the last check Monday.

Momentum18.74

Growth12.51

QualityN/A

Value50.29

Short

Medium

Long